Recent scientific research indicates that GLP-1 drugs, which are used to treat Type 2 Diabetes, can potentially reduce the incidence of heart complications.
A scientific study has shown that elderly patients on GLP-1 therapy have about a 20% lower risk of major cardiovascular events compared to users of other diabetes medications.
Experts explain that these drugs can improve cardiovascular health by promoting weight loss, regulating blood pressure, and improving lipid profile.
Additionally, GLP-1 drugs have anti-inflammatory and anti-atherosclerotic effects.
Patients diagnosed with Type 2 Diabetes already know that they are at greater risk of heart problems, and new research shows that a specific group of drugs can help reduce severe cardiovascular complications.
A study conducted at Vanderbilt University Medical Center indicated that GLP-1 drugs, such as Ozempic, may reduce the incidence of major cardiovascular events (MACE) compared to DPP4 inhibitors in elderly patients without heart disease.
The use of GLP-1 receptor agonists is associated with a 20% reduction in the risk of MACE and heart failure hospitalization compared with DPP4 inhibitors, which are neutral with respect to cardiac complications.
Per 1,000 people who use a GLP-1 drug for a year, there are about three fewer episodes of heart failure, heart attack, or stroke. Scientists note that these results will help doctors to better choose therapy for the treatment of diabetes in elderly patients.
Dr. Christianne Roumie, professor of medicine in the Department of Internal Medicine and Public Health and lead author of the study, describes the research as a “contribution to patient care” and adds that it “complements our knowledge of diabetes management and heart disease prevention.”
Why These Medications May Help Reduce Risks of Adverse Cardiac Events
“GLP-1 drugs are considered a promising option for the treatment of Type 2 Diabetes, because in addition to blood sugar control, they can contribute to weight loss and reduce the risk of heart disease,” explains Barry Stricoff, registered dietitian at Well Easy.
Stricoff points out that the lower risk of cardiovascular disease in patients taking GLP-1 drugs compared to DPP inhibitors comes from their positive effect on heart risk factors. “GLP-1 receptor agonists not only lower blood sugar levels, but also provide additional cardiovascular benefits, ” she adds.
“Obesity is a significant risk factor for heart disease, and GLP-1 receptor agonists help reduce weight by reducing appetite and increasing satiety,” explains Stricoff. “Some GLP-1 drugs show the ability to lower blood pressure, a key cardiovascular risk factor.
Stricoff adds that some research suggests that GLP-1 drugs have anti-inflammatory and anti-atherosclerotic effects, which may further reduce the risk of heart disease.
“These drugs can also have a positive effect on the lipid profile, for example by reducing triglycerides, contributing to reducing the risk of cardiovascular events,” adds Stricoff.
Crystal Scott, registered dietitian at Top Nutrition Coaching, notes that the results of this study support research linking GLP-1 medications to cardiovascular health in patients diagnosed with Type 2 Diabetes.
Like Stricoff, she highlights the cardioprotective effects of GLP-1 drugs, explaining that they can improve endothelial function, reduce arterial stiffness, and modulate inflammatory processes that contribute to the development and progression of cardiovascular disease.
The Findings From the Study are Promising but More Research is Needed
The author points out that this scientific research was conducted as a retrospective observational study, which enables conclusions about cause-and-effect relationships but does not completely exclude the influence of potential confounding factors.
He emphasizes that future controlled trials are necessary to further verify the results and define the optimal application of these drugs for the prevention of cardiovascular disease in people with Type 2 Diabetes. The study population was limited to US veterans, which may limit the generalizability of findings to other demographic and clinical groups.
An additional limitation is that the study did not include an evaluation of the therapy’s long-term safety and efficacy, leaving room for further research.
Other Ways You Can Improve Your Heart Health Without Medication
Although scientific data suggest a potential reduction in the risk of adverse cardiovascular events in patients using GLP-1 drugs, Stricoff emphasizes that we must look at their role in a broader pathophysiological context.
These drugs primarily modify metabolic disorders and clinical manifestations of Type 2 Diabetes, without directly changing the basic etiological mechanisms of the development of this disease.
She points out that although GLP-1 agonists can have a transformative effect on patients, their use should not be an isolated therapeutic option. On the contrary, optimal effects are achieved when drugs are integrated into a multidisciplinary treatment plan that includes structured nutritional change, behavior modification, and long-term adoption of healthy lifestyle habits.
Pharmacotherapy is only one component of the broader picture of cardiovascular health. Stricoff further emphasizes that lifestyle factors – including diet, physical activity, and control of other risk factors – play a central role in reducing the overall risk of developing cardiovascular disease.
She explains that unhealthy lifestyle habits (inadequate diet, insufficient physical activity, and smoking) unite common risk factors for the development of Type 2 Diabetes and cardiovascular diseases. In people who already have diabetes, the presence of these factors further increases the likelihood of heart disease and deterioration of the overall cardiometabolic profile.
He further emphasizes that the use of GLP-1 inhibitors must be accompanied by interventions aimed at the underlying causes of the disease and that encourage permanent lifestyle changes. Drugs, themselves, are not enough if they are not integrated into a broader concept of lifestyle modification.
In this context, nutritional education plays a central role, enabling patients to understand the connection between nutrition and health, develop the ability to make informed decisions, and adopt sustainable eating patterns that can be sustained in the long term, even after the termination of the therapeutic protocol.
Specifically, Scott recommends a diet low in saturated and trans fat, sodium, and added sugars, with increased fiber, whole grains, fruits, and vegetables, to promote cardiovascular health and metabolic control.
In addition, she emphasizes the importance of regular physical activity, recommending at least 150 minutes of moderate-intensity activity per week, such as brisk walking, cycling, swimming, or dancing, to improve cardiovascular function and metabolic balance.
Although it is known that pharmacological therapies are often associated with potential side effects, data indicating an association of GLP-1 drugs with a reduced incidence of adverse cardiovascular events is encouraging news.
The results of this study may contribute to more informed clinical decision-making and to the individualization of the therapeutic approach in accordance with the patients’ assessed risk and needs.
However, despite their potential effectiveness, both experts emphasize that pharmacotherapy cannot replace the basic principles of prevention. Long-term preservation of cardiovascular health and diabetes control requires consistent adherence to basic measures – proper nutrition, regular physical activity, and the elimination of cigarettes – that remain key pillars of a comprehensive therapeutic approach.
